LYEL Stock Summary and Trading Ideas (Lyell Immunopharma | NASDAQ:LYEL)

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Lyell Immunopharma trades on the NASDAQ stock market under the symbol LYEL.

As of November 6, 2026, LYEL stock price declined to $14.86 with 244,746 million shares trading.

LYEL has a beta of 1.40, meaning it tends to be more sensitive to market movements. LYEL has a correlation of 0.04 to the broad based SPY ETF.

LYEL has a market cap of $364.13 million. This is considered a Small Cap stock.

Last quarter Lyell Immunopharma reported $3,000 in Revenue and -$1.86 earnings per share. This fell short of revenue expectation by $-290 and exceeded earnings estimates by $.06.

In the last 3 years, LYEL traded as high as $65.11 and as low as $7.20.

The top ETF exchange traded funds that LYEL belongs to (by Net Assets): VTI, IWM, IWN, VXF, IBB.

LYEL has underperformed the market in the last year with a return of -16.9%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in LYEL shares. However, LYEL has outperformed the market in the last 3 month and 2 week periods, returning +4.6% and +58.3%, while SPY returned -4.1% and -3.2%, respectively. This indicates LYEL has been having a stronger performance recently.

LYEL support price is $13.89 and resistance is $16.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LYEL shares will trade within this expected range on the day.